Chronic myelogenous leukaemia (CML) is a clonal haematological disorder that is characterized by a reciprocal translocation between chromosomes 9 and 22, and provided the first evidence of a specific genetic change associated with human cancer.
The molecular consequence of this interchromosomal exchange is the creation of the BCR–ABL gene, which encodes a protein with elevated tyrosine-kinase activity. The demonstration that the creation of BCR–ABL is the molecular pathogenic event in CML provided the first potential drug target that clearly differed in its activity between normal and leukaemic cells.
Importantly, BCR–ABL could be approached with classical tools of pharmacology, as its activity could clearly be described and measured in biochemical as well as cellular assays. Furthermore, cell lines derived from human leukaemic cells with the same chromosomal abnormality were available.
A lead compound identified in a screen for inhibitors of protein kinase C was optimized to give a methyl-piperazine derivative that was originally named STI571 (imatinib, now known as Glivec or Gleevec), which was selected as the most promising candidate for clinical development.
In in vitro screens against a panel of protein kinases, Glivec was found to inhibit the autophosphorylation of essentially three kinases: BCR–ABL, c-KIT and the platelet-derived growth factor (PDGF) receptor.
Promising in vivo results — for example, with BCR–ABL-transformed cells in syngeneic mice — coupled with the facts that CML is essentially caused by a single molecular defect and that responses in CML can be measured easily using blood leukocyte count as the end point, led to CML being selected as the first indication for Phase I clinical testing of Glivec.
The clinical development of Glivec was extremely rapid; the first patient was treated in June 1998, and less than three years later, on the basis of three large, multinational trials that showed Glivec to be safe and effective in all stages of CML, Glivec was approved by the FDA in May 2001. European and Japanese approval followed in November 2001.
Current studies are investigating the activity of Glivec in cancers in which c-KIT and PDGF receptors might represent promising therapeutic targets. For example, gastrointestinal stromal tumours (GIST) are characterized by gain-of-function mutations in the KIT gene, and in February 2002, Glivec was approved by the FDA for the treatment of GIST.
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.
Subscribe to Journal
Get full journal access for 1 year
only $22.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rowley, J. D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290–293 (1973).
Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960).
Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the p210Bcr/Abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990).
Kelliher, M. A. et al. Induction of chronic myelogenous leukemia in mice by the v-Abl and Bcr/Abl. Proc. Natl Acad. Sci. USA 87, 6649–6653 (1990).
Heisterkamp, N. et al. Acute leukaemia in Bcr/Abl transgenic mice. Nature 344, 251–253 (1990).
Lugo, T. G. et al. Tyrosine kinase activity and transformation potency of Bcr–Abl oncogene products. Science 247, 1079–1082 (1990).
Lipinsky, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249 (2001).
Teague, S. et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Edn Eng. 38, 3743–3748 (1999).
Zimmermann, J. et al. (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6, 1221–1226 (1996).
Zimmermann, J. et al. Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7, 187–192 (1997).
Zimmerman, J., Furet, P. & Buchdunger, E. STI571. A new treatment modality for CML. ACS Symp. Ser. 796, 245–259 (2001).
Schindler, T. et al. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase. Science 289, 1938–1942 (2000).The first description of the structural interactions between Glivec and ABL using crystallographic studies. Provided an important insight into potential mechanisms of resistance.
Okuda, K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 97, 2440–2448 (2001).
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nature Med. 2, 561–566 (1996).The first study to document the strong efficacy of Glivec in in vitro and in vivo models of BCR–ABL-positive leukaemias.
Carroll, M. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947–4952 (1997).
Beran, M. et al. Selective inhibition of cell proliferation and BCR–ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR–ABL protein by a tyrosine kinase inhibitor (CGP 57148). Clin. Cancer Res. 4, 1661–1672 (1998).
Gambacorti-Passerini, C. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23, 380–394 (1997).
Deininger, M. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR–ABL-positive cells. Blood 90, 3691–3698 (1997).
Dan, S., Naito, M. & Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148B. Cell Death Differ. 5, 710–715 (1998).
Le Coutre, P. et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst. 91, 163–168 (1999).
Wolff, N. C. & Ilaria, R. L. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98, 2808–2816 (2001).
Sillaber, C. et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95, 2118–2125 (2000).
Horita, M. et al. Blockade of the Bcr–Abl kinase activity induces apoptosis of chronic myeloid leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of BCL-XL . J. Exp. Med. 191, 977–984 (2000).
Oda, T. et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925–22928 (1994).
Jonuleit, T. et al. Bcr–Abl kinase downregulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96, 1933–1939 (2000).
Gesbert, F. et al. BCR/ABL regulates expression of the cyclin dependent kinase inhibitor p27Kip1 through the PI3K/AKT pathway. J. Biol. Chem. 50, 39223–39230 (2000).
Gaston, I. et al. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr–Abl transformed cells. Exp. Hematol. 28, 77–86 (2000).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).The first clinical results with Glivec in CML, documenting a high level of efficacy, low level of toxicity and describing the dose–response relationship. These results confirm the crucial role of BCR–ABL in the pathophysiology of CML.
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
Peng, B. et al. Clinical investigation of the PK/PD relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol. 20, 280 (2001).
Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002).
Talpaz, M. et al. Glivec™ (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99, 1928–1937 (2002).
Sawyers, C. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood 99, 3530–3539 (2002).
Weisberg, E. & Griffin, J. Mechanism of resistance to the Abl tyrosine kinase inhibitor STI571in BCR/ABL transformed hematopoietic cell lines. Blood 95, 3498–3505 (2000).
Mahon, F. et al. Selection and characterization of BCR–ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070–1079 (2000).
Le Coutre, P. et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95,1758–1766 (2000).
Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).This study describes potential mechanisms of resistance in CML in clinical samples from treated patients.
Gorre, M. E. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001).
Barthe, C. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001).
Hochhaus, A. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001).
Von Bubnoff, N. et al. BCR–ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487–491 (2002).
Manley, P. W. et al. Molecular interactions between Gleevec™ and isoforms of the c-Abl kinase. Proc. Am. Assoc. Cancer Res. 4196 (2002).
Gambacorti-Passerini, C. et al. α1 Acidic glycoprotein (AGP) binds, inhibits and causes in vivo resistance of human BCR–ABL+ leukemic cells to STI571. J. Natl Cancer Inst. 92, 1641–1650 (2000).
Jorgensen, H. G. et al. α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99, 713–715 (2002).
Hofmann, W. K. et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359, 481–486 (2002).
Druker, B. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN)+ cytarabine as initial therapy for patients with CML: results of a randomized study. Proc. Am. Soc. Clin. Oncol. 1 (2002).
Buchdunger, E. et al. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J. Pharmacol. Exp. Ther. 295, 139–145 (2000).
Heinrich, M. C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96, 925–932 (2000).
Hirota, S. et al. Gain of function mutations of c-Kit in human gastrointestinal stromal tumors. Science 279, 577–580 (1998).This study establishes the importance of c-KIT signalling in the pathogenesis of GIST tumours.
Lasota, J. et al. Mutations in exons 9 and 13 of Kit gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. Am. J. Pathol. 157, 1091–1095 (2000).
Lux, M. L. et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 156, 791–795 (2000).
Rubin, B. P. et al. Kit activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118–8121 (2001).
Heinrich, M. C. et al. STI571 inhibits the kinase activity of wild type and juxtamembrane c-Kit mutants but not the exon 17 D816V mutations associated with mastocytosis. Blood 96, 4459 (2000).
Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001).
Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052–1056 (2001).A proof-of-concept report of the efficacy of Glivec in KIT-expressing GIST, and rationale for further development in this indication, as well as in other solid tumours that express KIT.
Van Oosterom, A. T. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors, a phase I study. Lancet 358, 1421–1423 (2001).
Blanke, C. D. et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117). Proc. Am. Soc. Clin. Oncol. 20, 1 (2001).
Heinrich, M. C. et al. Inhibition of Kit kinase activity: a novel molecular approach to the treatment of Kit-positive malignancies. J. Clin. Oncol. 20, 1692–1703 (2002).An excellent review of KIT as a target for anticancer therapy.
Krystal, G. W., Hines, S. & Organ, C. Autocrine growth of small cell lung cancer mediated by co-expression of c-kit and stem cell factor. Cancer Res. 56, 370–376 (1996).
Krystal, G. W., Carlson, P. & Litz, J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrophostins. Cancer Res. 57, 2203–2208 (1997).
Krystal, G. W. et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6, 3319–3326 (2000).
Wang, W. L. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI571. Oncogene 19, 3521–3528 (2000).
Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).
Östman, A. & Heldin, C. H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80, 1–38 (2001).
Nistér, M. et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. 266, 16755–16763 (1991).
Kilic, T. et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyridine class. Cancer Res. 60, 5143–5150 (2000).
Shimizu, A. et al. The dermatofibrosarcoma protuberans-associated collagen type 1α/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59, 3719–3723 (1999).
Greco, A. et al. Growth inhibitory effect of STI571 on cells transformed by the COL1A/PDGFB rearrangement. Int. J. Cancer 92, 354–360 (2001).
Sjöblom, T. et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61, 5778–5783 (2001).
Awan, R. A. et al. Patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans (DFSP) may respond to imatinib (STI571, Gleevec). Proc. Am. Soc. Clin. Oncol. 1637 (2002).
Jousset, C. et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein. EMBO J. 16, 69–82 (1997).
Tomasson, M. H. et al. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93, 1707–1714 (1999).
Apperley, J. F. et al. Chronic myeloproliferative diseases with t(5:12) and a PDGFRB fusion gene: complete cytogenetic remission with STI571. Blood 98, 726A (2001).A proof-of-concept study of the efficacy of Glivec in a PDGFR-driven malignancy.
Gullberg, D. et al. α1 Integrin-mediated collagen gel contraction is stimulated by PDGF. Exp. Cell Res. 186, 264–272 (1990).
Rodt, S. A. et al. A novel physiologic role for platelet-derived growth factor-BB in rat dermis. J. Physiol. (Lond.) 495, 193–200 (1996).
Heuchel, R. et al. Platelet-derived growth factor receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3 kinase signaling. Proc. Natl Acad. Sci. USA. 20, 11410–11415 (1999).
Jain, R. K. Delivery of molecular medicine to solid tumors. Science 271, 1079–1080 (1996).
Pietras, K. et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929–2934 (2001).
Hellström, M. et al. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Exp. Cell Res. 186, 264–272 (1999).
Reinmuth, N. et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239–1241 (2001).
Wang, D. et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 59, 1464–1472 (1999).
Buchdunger, E., O'Reilly, T. & Wood, J. Pharmacology of imatinib (STI571). Eur. J. Cancer (in the press).
Uehara, H. et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice. Proc. Am. Assoc. Cancer Res. 2192 (2001).
We would like to thank the members of the Glivec International Project Team for their crucial contribution to the success of this programme and their kind review of this manuscript: P. Boultbee, V. Buss, S. Dimitrijevic, A. Dortok, D. Filipovic, I. Gathmann, H. Godman, J. Jaffe, L. Letvak, P. Marbach, R. Miranda, J. Ogorka, C. Ogawa, B. Peng, S. Silberman, F. Sutter, S. Szabo, S. Wells and J. M. Ford. We also thank B. Druker for his crucial input and a fruitful collaboration throughout this programme, and N. Lydon for his contribution in the early phase of the programme. We thank also C. Schmid for her assistance in editing the manuscript.
Leukaemia is an uncontrolled proliferation of one type of white blood cell (leukocyte).
Programmed cell death.
- SYNGENEIC MODEL
An animal model in which the injected tumour cells are derived from the same animal species as the host animal.
- GRADE III–IV ADVERSE EVENTS
For each adverse event that is associated with a specific treatment, grades are assigned and defined using a scale from 0 to V. Grade III, severe and undesirable adverse event; grade IV, life-threatening or disabling adverse event.
Describes an agent secreted from a cell that acts on the cell in which it is produced.
Describes an agent secreted from a cell that acts on other cells in the local environment.
About this article
Cite this article
Capdeville, R., Buchdunger, E., Zimmermann, J. et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1, 493–502 (2002). https://doi.org/10.1038/nrd839
Integrative X-ray Structure and Molecular Modeling for the Rationalization of Procaspase-8 Inhibitor Potency and Selectivity
ACS Chemical Biology (2020)
Visible-Light-Induced C–C Coupling Reaction to Synthesize Bipyridine From 3-Cyano-1,4-Dihydropyridines
Frontiers in Chemistry (2020)
Ligand-free Suzuki coupling reaction with highly recyclable ionic palladium catalyst, Ti1-xPdxO2-x (x = 0.03)
Applied Catalysis A: General (2020)
Journal of Medicinal Chemistry (2020)
Nature Chemical Biology (2020)